Document is current
Any future updates will be listed below
-
Authors
Nowicki, Theodore S. https://orcid.org/0000-0002-3815-6137
Deen, Nataly Naser Al
Peters, Cole W. https://orcid.org/0000-0001-7052-1432
Comin-Anduix, Begoña
Medina, Egmidio https://orcid.org/0000-0002-3284-5329
Puig-Saus, Cristina https://orcid.org/0000-0002-3014-3649
Carretero, Ignacio Baselga
Kaplan-Lefko, Paula
Macabali, Mignonette H. https://orcid.org/0009-0007-9861-7234
Garcilazo, Ivan Perez
Chen, Daniel https://orcid.org/0000-0001-6660-6257
Pang, Jia
Berent-Maoz, Beata
Haile, Salem
Rodriguez, Jonathan https://orcid.org/0000-0003-3201-3407
Kawakami, Moe https://orcid.org/0009-0008-6981-8114
Kidd, Conner K. https://orcid.org/0000-0002-0152-2877
Champhekar, Ameya
Carlucci, Giuseppe
Vega-Crespo, Agustin
Chmielowski, Bartosz https://orcid.org/0000-0002-2374-3320
Singh, Arun
Federman, Noah
Schiller, Gary M. https://orcid.org/0000-0002-7508-3467
Larson, Sarah J.
Allen-Auerbach, Martin
Klomhaus, Alexandra M. https://orcid.org/0000-0002-7676-3595
Zack, Jerome
Baltimore, David https://orcid.org/0000-0001-8723-8190
Yang, Lili
Kohn, Donald B. https://orcid.org/0000-0003-1840-6087
Witte, Owen N.
Ribas, Antoni https://orcid.org/0000-0003-3669-8458
-
Funding
Funding for this research was provided by:
California Institute for Regenerative Medicine (CLIN2-11380, INFR4 Alpha Clinic Network Expansion Award)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08 CA241088, R35 CA197633)
Hyundai Motor Group | Hyundai Motor America | Hyundai Hope On Wheels
Tower Cancer Research Foundation
U.S. Department of Health & Human Services | National Institutes of Health (UL1TR001881)
- License Information
-
More Information
Article History
Received: 27 September 2024
Accepted: 29 May 2025
First Online: 1 July 2025
Competing interests
: TSN reports consulting honoraria from Allogene Therapeutics, PACT Pharma, Adaptive Biotechnologies, and Medidata Solutions. NF has received honoraria for speaker’s bureaus and advisory boards from Bayer AG, Fennec Pharmaceuticals, and Springworks Therapeutics, and holds stock ownership in Moderna, Bolt Biotherapeutics, Regulus, Bluebird Bio, and 2seventy Bio. BC has received honoraria for consulting and advisory boards from Novartis, Delcath Systems, Instil Bio, Replimune, Atreca, Regeneron, Treeline Biosciences, and SpringWorks Therapeutics, and has received research funding from Bristol-Myers Squibb, Macrogenics, Karyopharm Therapeutics, Infinity Pharmaceuticals, Advenchen Laboratories, Xencor, Compugen, Iovance Biotherapeutics, RAPT Therapeutics, IDEAYA Biosciences, Ascentage Pharma, Atreca. Replimune, Instil Bio, Adagene, TriSalus Life Sciences, Kinnate Biopharma, PTC Therapeutics, Xilio Therapeutics, Kezar Life Sciences, Immunocore, AskGene Pharma. O.N.W. currently has consulting, equity, and/or board relationships with Trethera Corporation, Kronos Biosciences, Sofie Biosciences, Breakthrough Properties, Vida Ventures, Nammi Therapeutics, Two River, Iconovir, Appia BioSciences, Neogene Therapeutics, 76Bio, and Allogene Therapeutics. A.R. has received honoraria from consulting with Amgen and Roche-Genentech, is or has been a member of the scientific advisory board, and holds stock in Appia, Apricity, Arcus, Compugen, CytomX, ImaginAb, ImmPact, Inspirna, Kite-Gilead, Larkspur, Lutris, MapKure, Merus, Synthekine, and Tango, has received research funding from Agilent and from Bristol-Myers Squibb through Stand Up to Cancer (SU2C), and patent royalties from Arsenal Bio. None of these companies contributed to or directed any of the research reported in this article. D.B. and L.Y. are inventors on patents related to this study filed by California Institute of Technology. All other authors have no competing interests to declare.
